NASDAQ:SPHSSophiris Bio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sophiris Bio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.01 0.00 (0.00 %) (As of 07/7/2020 11:44 AM ET) Add Compare Share Today's Range$0.01Now: $0.01▼$0.0250-Day Range$0.00MA: $0.02▼$0.2252-Week Range$0.00Now: $0.01▼$1.17Volume431,200 shsAverage Volume485,139 shsMarket Capitalization$355,500.00P/E RatioN/ADividend YieldN/ABeta2.28 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSophiris Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.80, Sophiris Bio has a potential upside of 27,900.0% from its current price of $0.01.Amount of Analyst CoverageSophiris Bio has received no research coverage in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesSophiris Bio has received 300 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSophiris Bio has received 184 “underperform” votes. (Add your “underperform” vote.)Community SentimentSophiris Bio has received 61.98% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote “Outperform” if you believe SPHS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSophiris Bio does not currently pay a dividend.Dividend GrowthSophiris Bio does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sophiris Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of Sophiris Bio is held by insiders.Percentage Held by InstitutionsOnly 9.30% of the stock of Sophiris Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sophiris Bio are expected to remain at ($0.34) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sophiris Bio is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sophiris Bio is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSophiris Bio has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.45 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPHS Previous Symbol CUSIPN/A CIK1563855 Webwww.sophirisbio.com Phone858-777-1760Debt Debt-to-Equity RatioN/A Current Ratio1.79 Quick Ratio1.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.06 per share Price / Book0.17Profitability EPS (Most Recent Fiscal Year)($0.52) Net Income$-6,780,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-110.71%Miscellaneous Employees6 Outstanding Shares35,550,000Market Cap$355,500.00 Next Earnings Date8/14/2020 (Estimated) OptionableOptionable NASDAQ:SPHS Rates by TradingView Receive SPHS News and Ratings via Email Sign-up to receive the latest news and ratings for SPHS and its competitors with MarketBeat's FREE daily newsletter. Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions How has Sophiris Bio's stock been impacted by COVID-19 (Coronavirus)? Sophiris Bio's stock was trading at $0.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SPHS stock has decreased by 95.7% and is now trading at $0.01. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Sophiris Bio? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sophiris Bio. When is Sophiris Bio's next earnings date? Sophiris Bio is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Sophiris Bio. How were Sophiris Bio's earnings last quarter? Sophiris Bio Inc (NASDAQ:SPHS) posted its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. View Sophiris Bio's earnings history. What price target have analysts set for SPHS? 1 brokerages have issued 12-month target prices for Sophiris Bio's shares. Their forecasts range from $2.80 to $2.80. On average, they expect Sophiris Bio's stock price to reach $2.80 in the next year. This suggests a possible upside of 27,900.0% from the stock's current price. View analysts' price targets for Sophiris Bio. Has Sophiris Bio been receiving favorable news coverage? Media headlines about SPHS stock have trended negative recently, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sophiris Bio earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Sophiris Bio. Who are some of Sophiris Bio's key competitors? Some companies that are related to Sophiris Bio include THERAPIX BIOSCI/S (TRPX), Capstone Therapeutics (CAPS), Praxsyn (PXYN), Peak Pharmaceuticals (PKPH), Cotinga Pharmaceuticals (COTQF), Achaogen (AKAOQ), Argos Therapeutics (ARGSQ), Sienna Biopharmaceuticals (SNNAQ), Targeted Medical Pharma (TRGM), ProMetic Life Sciences (PFSCF), Spotlight Innovation (STLT), HST Global (HSTC), Skinvisible (SKVI), Propanc Biopharma (PPCB) and Orexigen Therapeutics (OREXQ). View all competitors. What other stocks do shareholders of Sophiris Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sophiris Bio investors own include Sarepta Therapeutics (SRPT), Intercept Pharmaceuticals (ICPT), Celator Pharmaceuticals (CPXX), SLS International (SLS), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), Heat Biologics (HTBX), Novavax (NVAX), Verastem (VSTM) and SCYNEXIS (SCYX). Who are Sophiris Bio's key executives? Sophiris Bio's management team includes the following people: Dr. Lars G. Ekman M.D., Ph.D., Exec. Chairman (Age 69)Mr. Randall E. Woods, CEO, Pres & Director (Age 67)Mr. Peter T. Slover, Chief Financial Officer (Age 44)Dr. Allison J. Hulme, COO, Head of R&D and Director (Age 56)Dr. Samuel R. Denmeade, Chief Scientific Officer & Member of the Scientific Advisory Board What is Sophiris Bio's stock symbol? Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS." How do I buy shares of Sophiris Bio? Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Sophiris Bio's stock price today? One share of SPHS stock can currently be purchased for approximately $0.01. How big of a company is Sophiris Bio? Sophiris Bio has a market capitalization of $355,500.00. The biopharmaceutical company earns $-6,780,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe. What is Sophiris Bio's official website? The official website for Sophiris Bio is www.sophirisbio.com. How can I contact Sophiris Bio? Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected] This page was last updated on 7/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
